Janssen Executive Says Doxil Shortage Likely, Due to Contract Manufacturer

The president of Janssen Products LP said in late September that shortages of the cancer drug Doxil (doxorubicin HCl liposome injection) are likely to occur due to problems with its contract manufacturer.

Doxil is used in multiple treatment regimens, including treatment of ovarian cancer after failure of platinum-based chemotherapy. The drug also is indicated for use in AIDS-related Kaposi’s sarcoma and multiple myeloma.

In a message posted on Janssen’s website, Janssen president Rob Bazemore said “[a]n issue at Ben Venue Laboratories, Inc., our contract manufacturer, has resulted in a manufacturing delay.”

Bazemore said that because of the issue with the ...